CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
暂无分享,去创建一个
F. Bertucci | D. Birnbaum | P. Finetti | T. K. van den Berg | T. Kuijpers | T. Matozaki | Hans van der Maaden | A. van Elsas | X. W. Zhao | M. van Egmond | G. Kraal | M. van Houdt | K. Schornagel | Xi Wen Zhao | Ellen M van Beek | M. Otten | Ellen M. van Beek
[1] Eric J. Brown,et al. Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and Its Cognate Receptor Signal-Regulator Protein-α: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation1 , 2001, The Journal of Immunology.
[2] A. Ullrich,et al. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. , 2001, Blood.
[3] T. K. van den Berg,et al. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. , 1998, Journal of immunology.
[4] J. Mcwhirter,et al. CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy , 2007, The Journal of Immunology.
[5] A. Houghton,et al. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein , 1995, The Journal of experimental medicine.
[6] E. Vitetta,et al. A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies , 2004, Clinical Cancer Research.
[7] E. Winer,et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.
[8] A. Ullrich,et al. Signal-regulatory protein a ( SIRP a ) but not SIRP b is involved in T-cell activation , binds to CD 47 with high affinity , and is expressed on immature CD 34 1 CD 38 2 hematopoietic cells , 2001 .
[9] A. Barclay,et al. CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1 , 2000, European journal of immunology.
[10] J. Dick,et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells , 2007, Nature Immunology.
[11] D. Stuart,et al. Structure of Signal-regulatory Protein α , 2009, The Journal of Biological Chemistry.
[12] Daniel Birnbaum,et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.
[13] P. Bruhns,et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. , 2005, Blood.
[14] Ash A. Alizadeh,et al. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.
[15] H. Gresham,et al. Cd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis , 2001, The Journal of experimental medicine.
[16] A. Barclay,et al. The SIRP family of receptors and immune regulation , 2006, Nature Reviews Immunology.
[17] Ash A. Alizadeh,et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. , 2011, Cancer research.
[18] C. Lagenaur,et al. Role of CD47 as a marker of self on red blood cells. , 2000, Science.
[19] T. Berg,et al. Innate immune ‘self’ recognition: a role for CD47–SIRPα interactions in hematopoietic stem cell transplantation , 2008 .
[20] E. Sausville,et al. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. , 2007, The oncologist.
[21] S. Akira,et al. Negative Regulation of Platelet Clearance and of the Macrophage Phagocytic Response by the Transmembrane Glycoprotein SHPS-1* , 2002, The Journal of Biological Chemistry.
[22] C. Lagenaur,et al. Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule* , 1999, The Journal of Biological Chemistry.
[23] T. Matozaki,et al. SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. , 2006, Blood.
[24] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[25] M. Kasuga,et al. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion , 1996, Molecular and cellular biology.
[26] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Glennie,et al. Renaissance of cancer therapeutic antibodies. , 2003, Drug discovery today.
[28] T. K. van den Berg,et al. Signal Regulatory Proteins in the Immune System , 2005, The Journal of Immunology.
[29] R. Dillman,et al. Monoclonal antibodies in cancer therapy: 25 years of progress. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Daniel Birnbaum,et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.
[31] T. Matozaki,et al. Negative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System1 , 2005, The Journal of Immunology.
[32] A. Saven,et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Kretz-Rommel,et al. Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy , 2008, The Journal of Immunology.
[34] A. Ullrich,et al. A family of proteins that inhibit signalling through tyrosine kinase receptors , 1997, Nature.
[35] J. Isola,et al. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , 2007, Molecular Cancer Therapeutics.
[36] B. Neel,et al. Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages , 1998, Molecular and Cellular Biology.
[37] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[38] J. V. D. van de Winkel,et al. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. , 2003, Blood.